Benzinga | Nov 23, 2021 09:22AM EST

SVB Leerink Maintains Outperform on Amryt Pharma, Lowers Price Target to $19

SVB Leerink analyst Mani Foroohar maintains Amryt Pharma (NASDAQ:AMYT) with a Outperform and lowers the price target from $23 to $19.